7. Innate Immun 2011,17(6):532–540.Omipalisib mouse PubMedCrossRef 39. Myers ND, Chantratita N, Berrington WR, Chierakul W, Limmathurotsakul D, Wuthiekanun V, Robertson JD, Liggitt HD, Peacock SJ, Skerrett SJ, West TE: The Role of NOD2 in Murine and Human Melioidosis. J Immunol 2014,192(1):300–307.PubMedCrossRef 40. Liu B, Koo GC, Yap EH, Chua KL, Gan YH: Model of differential susceptibility

to mucosal Burkholderia pseudomallei infection. Infect Immun 2002,70(2):504–511.PubMedCentralPubMedCrossRef 41. Brett PJ, DeShazer D, Woods DE: Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int J Syst Bacteriol 1998,48(Pt 1):317–320.PubMedCrossRef this website 42. Schafer A, Tauch A, Jager W, Kalinowski J, Thierbach G, Puhler A: Small mobilizable multi-purpose cloning vectors derived from the Escherichia coli plasmids pK18 and pK19: selection of defined deletions in the chromosome of Corynebacterium glutamicum. Gene 1994,145(1):69–73.PubMedCrossRef 43. Choi KH, Mima T, Casart Y, Rholl D, Kumar A, Beacham IR, Schweizer HP: Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl Environ Microbiol 2008,74(4):1064–1075.PubMedCentralPubMedCrossRef 44. Koka V,

Huang XR, Chung AC, Wang W, Truong LD, Lan HY: Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008,172(5):1174–1183.PubMedCentralPubMedCrossRef Competing interests The authors declare that they have DOK2 no competing interests. Authors’ contributions BET, CTF, YHG designed the experiments. BET, YC, CRT0066101 mouse IGJC and CTF performed

the experiments. BET, YC, CTF, YHG analyzed the results. THW, ES, PYC and MAT set up the photothermal nanoblade experiments. YHG conceived the study and together with CTF and JFM wrote the manuscript. All authors read and approved the final manuscript.”
“Background Despite the availability of an effective treatment for decades, tuberculosis (TB) continues to cause great mortality and suffering, especially in poor and less-developed countries. Its association with the HIV/AIDS pandemic forms a lethal combination. In addition, multidrug resistant (MDR) TB and the recently-described extensively drug resistant (XDR) TB severely complicate the management and control of the disease worldwide [1, 2]. Almost 8.8 million new cases of TB were reported in 2010, and 1.4 million deaths were attributed to the disease. Asia and Sub-Saharan Africa accounted for 85% of new cases of TB worldwide [3]. Of the 8.8 million incident cases in 2010, 1.1 million (13%) were among people living with HIV. Tuberculosis remains a common disease in Cameroon, with an estimated of 25 000 cases annually [4]. Like in other poor resources countries, therapeutic decisions are most often made by algorithms according to WHO guidelines.